Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 13 - Mar. 31, 2017
  • Conversation with the Cancer Letter

    Amy Abernethy: I want health IT companies to have an honest conversation about data sharing

    It’s fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.

  • Genentech’s rituximab SC received unanimous ODAC approval recommendation

    The FDA Oncologic Drugs Advisory Committee March 29 unanimously recommended approval of a lymphoma treatment, to be administered via subcutaneous injection.

  • In Brief

    • Carlo Croce to receive 2017 AACR Margaret Foti Award for leadership, achievements in research
    • Roger Lo to receive AACR-Waun Ki Hong award for outstanding achievement in cancer research
    • Bezos family donates $35M to Fred Hutchinson
    • Cancer death rates continue to decrease
    • NCCN publishes Radiation Therapy Compendium
    • NCCN Foundation awards grants to four young investigators
    • Friends launches ProgressForPatients.org
    • Health coalition forms National Lung Cancer Roundtable
    • Columbia, New York-Presbyterian, FNIH enter research collaboration
    • The Mikey Czech Foundation Contributes $1 Million To DIPG Research at Dana-Farber
    • Jeffrey Ravetch gets Ross Prize in Molecular Medicine
    • Alan Bernstein awarded Friesen prize
  • Drugs and Targets

    • FDA approves AstraZeneca’s Tagrisso for EGFR mutation-positive NSCLC
    • FDA approves niraparib for epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • Gamida Cell receives EMA orphan drug designation for NiCord
    • Cota, Novartis form collaboration to advance real-world evidence in breast cancer therapies
    • Novartis CAR-T cell therapy for pediatric r/r B-cell ALL gets FDA Priority Review
    • BMS, Foundation Medicine form collaboration to identify predictive biomarkers across tumor types, immunotherapy agents
    • AbbVie, M2Gen announce collaboration for the ORIEN Avatar Research Program
March 2017PDF

 

Multiple Myeloma

Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.

 

Chronic Myeloid Leukemia

NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.

 

Breast Cancer

Phase III MONARCH 2 study of abemaciclib meets primary endpoint of PFS

Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase  4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.

 

Ovarian Cancer

Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease

AstraZeneca presented data from the confirmatory Phase III SOLO-2 trial demonstrating a statistically significant and clinically meaningful improvement of progression-free survival among patients treated with Lynparza (olaparib) compared to placebo.

 

Lung Cancer

Proton therapy offers treatment possibility for recurrent lung cancer

 

Bladder and Prostate Cancers

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

 

Medulloblastoma

St. Jude study reveals how an enzyme puts the brakes on aggressive disease

 

Health Disparities

Black and Hispanic women in Connecticut less likely to undergo gene expression profiling

 

NCI CTEP-Approved Trials for March

 

Regulatory Actions

Bavencio receives accelerated approval for Merkel cell carcinoma

CCL March 2017 - Mar. 30, 2017
Issue 12 - Mar. 24, 2017